Market closed
Arcutis Biotherapeutics/$ARQT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Ticker
$ARQT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
342
ISIN
US03969K1088
Website
ARQT Metrics
BasicAdvanced
$1.6B
-
-$1.04
1.87
-
Price and volume
Market cap
$1.6B
Beta
1.87
52-week high
$17.75
52-week low
$6.99
Average daily volume
2.4M
Financial strength
Current ratio
3.552
Quick ratio
3.111
Long term debt to equity
77.078
Total debt to equity
77.668
Interest coverage (TTM)
-5.35%
Management effectiveness
Return on assets (TTM)
-18.43%
Return on equity (TTM)
-70.58%
Valuation
Price to revenue (TTM)
7.928
Price to book
11.3
Price to tangible book (TTM)
12.78
Price to free cash flow (TTM)
-14.46
Growth
Revenue change (TTM)
100.03%
Earnings per share change (TTM)
-60.88%
3-year earnings per share growth (CAGR)
-39.39%
What the Analysts think about ARQT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Arcutis Biotherapeutics stock.
ARQT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ARQT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ARQT News
AllArticlesVideos
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
GlobeNewsWire·3 days ago
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript
Seeking Alpha·4 days ago
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Arcutis Biotherapeutics stock?
Arcutis Biotherapeutics (ARQT) has a market cap of $1.6B as of May 10, 2025.
What is the P/E ratio for Arcutis Biotherapeutics stock?
The price to earnings (P/E) ratio for Arcutis Biotherapeutics (ARQT) stock is 0 as of May 10, 2025.
Does Arcutis Biotherapeutics stock pay dividends?
No, Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Arcutis Biotherapeutics dividend payment date?
Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcutis Biotherapeutics?
Arcutis Biotherapeutics (ARQT) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.